1327P Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)

Sara Manglaviti ,Giuseppe Lo Russo ,Marina Chiara Garassino ,Arsela Prelaj ,Ernesto Zecca ,Mario Occhipinti ,Marta Bini ,Giulia Galli ,Alessandro De Toma ,Giulia Apollonio ,Teresa Beninato ,Marta Brambilla ,Giuseppe Viscardi ,Claudia Proto ,Diego Signorelli ,Alice Labianca ,Eugenio Galli ,Emma Zattarin ,F.G.M De Braud,Roberto Ferrara

doi:10.1016/j.annonc.2021.08.1928

1327P Impact of bone targeted agents (BTA) in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD(L)1 inhibitors (ICIs)

Sara Manglaviti , Giuseppe Lo Russo + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.1928

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
License type: publisher-specific-oa

Affiliation: Fondazione IRCCS Istituto Nazionale dei Tumori, University of Chicago, University of Campania "Luigi Vanvitelli", Ospedale Niguarda Ca' Granda

#Bone Targeted Agents #Bone Targeted Agents Use + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

BTA use in cancer pts with bone metastases (BM) can prevent skeletal related events. A subgroup analysis of aNSCLC pts showed an overall survival (OS) benefit with denosumab (DN) compared to zoledronic acid (ZA), while in the SPLENDOUR trial the addition of DN to 1st line chemotherapy did not improve OS. Currently, the impact of BTA in ICI treated BM aNSCLC remains unclear.

Full Text